Frontiers in Immunology (Oct 2022)
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
- Maura Pugliatti,
- Maura Pugliatti,
- Hans-Peter Hartung,
- Hans-Peter Hartung,
- Hans-Peter Hartung,
- Celia Oreja-Guevara,
- Celia Oreja-Guevara,
- Carlo Pozzilli,
- Laura Airas,
- Laura Airas,
- Mona Alkhawajah,
- Mona Alkhawajah,
- Nikolaos Grigoriadis,
- Melinda Magyari,
- Bart Van Wijmeersch,
- Bart Van Wijmeersch,
- Bart Van Wijmeersch,
- Magd Zakaria,
- Ralf Linker,
- Andrew Chan,
- Patrick Vermersch,
- Thomas Berger,
- Thomas Berger
Affiliations
- Maura Pugliatti
- Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy
- Maura Pugliatti
- Interdepartmental Center of Research for Multiple Sclerosis and Neuro-inflammatory and Degenerative Diseases, University of Ferrara, Ferrara, Italy
- Hans-Peter Hartung
- Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- Hans-Peter Hartung
- Brain and Mind Center, University of Sydney, Sydney, NSW, Australia
- Hans-Peter Hartung
- Department of Neurology, Palacky University Olomouc, Olomouc, Czechia
- Celia Oreja-Guevara
- Department of Neurology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain
- Celia Oreja-Guevara
- Faculty of Medicine, Complutense University of Madrid (UCM), Madrid, Spain
- Carlo Pozzilli
- Multiple Sclerosis Center, S. Andrea Hospital, Department of Human Neuroscience, University Sapienza, Rome, Italy
- Laura Airas
- Division of Clinical Neurosciences, University of Turku, Turku, Finland
- Laura Airas
- 0Neurocenter of Turku University Hospital, Turku, Finland
- Mona Alkhawajah
- 1Section of Neurology, Neurosciences Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
- Mona Alkhawajah
- 2College of Medicine, Al Faisal University, Riyadh, Saudi Arabia
- Nikolaos Grigoriadis
- 3Laboratory of Experimental Neurology and Neuroimmunology, Second Department of Neurology, American Hellenic Educational Progressive Association (AHEPA) University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
- Melinda Magyari
- 4Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- Bart Van Wijmeersch
- 5Universitair Multiple Sclerosis (MS) Centrum, Hasselt-Pelt, Belgium
- Bart Van Wijmeersch
- 6Revalidatie & Multiple Sclerosis (MS), Noorderhart, Pelt, Belgium
- Bart Van Wijmeersch
- 7Rehabilitation Research Center (REVAL) & Biomedical Research Institute (BIOMED), Hasselt University, Hasselt, Belgium
- Magd Zakaria
- 8Department of Neurology, Ain Shams University, Cairo, Egypt
- Ralf Linker
- 9Clinic and Polyclinic for Neurology, Universitätsklinikum Regensburg, Regensburg, Germany
- Andrew Chan
- 0Department of Neurology, Inselspital Bern, Bern University Hospital, University of Bern, Bern, Switzerland
- Patrick Vermersch
- 1University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France
- Thomas Berger
- 2Department of Neurology, Medical University of Vienna, Vienna, Austria
- Thomas Berger
- 3Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria
- DOI
- https://doi.org/10.3389/fimmu.2022.1045101
- Journal volume & issue
-
Vol. 13
Abstract
It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.
Keywords
